Stockscreener 앱 받기
0.7652
7.63%
-0.0632
시간 외 거래:
.81
0.0448
+5.85%
전일 마감가:
$0.8284
열려 있는:
$0.899
하루 거래량:
510.17K
Relative Volume:
1.96
시가총액:
$43.58M
수익:
$3.10M
순이익/손실:
$-97.43M
주가수익비율:
-0.3447
EPS:
-2.22
순현금흐름:
$-94.38M
1주 성능:
-29.80%
1개월 성능:
-27.81%
6개월 성능:
-68.25%
1년 성능:
-64.24%
1일 변동 폭
$0.75
$0.9299
1주일 범위
$0.75
$1.17
52주 변동 폭
$0.75
$6.30
Omega Therapeutics Inc Stock (OMGA) Company Profile
명칭
Omega Therapeutics Inc
전화
(617) 949-4360
주소
140 FIRST STREET, SUITE 501, CAMBRIDGE
OMGA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| OMGA | 0.7652 | 43.58M | 3.10M | -97.43M | -94.38M | -2.22 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Omega Therapeutics Inc Stock (OMGA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-08 | 개시 | H.C. Wainwright | Buy |
| 2022-09-23 | 개시 | Chardan Capital Markets | Buy |
Omega Therapeutics Inc 주식(OMGA)의 최신 뉴스
Omega Therapeutics Reports Third Quarter 2024 Results - TipRanks
Omega Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance
Shares of Flagship-founded biotech fall as CEO departs - The Business Journals
Omega Therapeutics (NASDAQ:OMGA) Downgraded to Market Perform Rating by Raymond James - MarketBeat
Piper Sandler Issues Pessimistic Forecast for Omega Therapeutics (NASDAQ:OMGA) Stock Price - MarketBeat
Omega Therapeutics Inc (OMGA) Quarterly 10-Q Report - Quartzy
Omega Therapeutics, Inc. (OMGA) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Omega Therapeutics Names Kaan Certel as CEO - MarketWatch
Omega Therapeutics Announces Successful Completion of Phase - GlobeNewswire
Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results - The Manila Times
Omega Therapeutics, Inc. Announces Chief Executive Officer Changes - Marketscreener.com
Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner - Financial Times
Omega Therapeutics (NASDAQ:OMGA) Stock Price Down 0.9%Should You Sell? - MarketBeat
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Oculis Holding AG (OCS) Moves 7.9% Higher: Will This Strength Last? - Yahoo Finance
Zura Bio (NASDAQ:ZURA) versus Omega Therapeutics (NASDAQ:OMGA) Critical Contrast - Defense World
Omega Therapeutics stock hits 52-week low at $0.94 By Investing.com - Investing.com Australia
Cubist Systematic Strategies LLC Grows Holdings in Omega Therapeutics, Inc. (NASDAQ:OMGA) - Defense World
Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings - The Manila Times
Omega Therapeutics to Present Multiple Posters Highlighting - GlobeNewswire
Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions - Financial Times
Omega Therapeutics stock hits 52-week low at $1.07 By Investing.com - Investing.com Australia
Omega Therapeutics stock hits 52-week low at $1.07 - Investing.com India
Omega Therapeutics Appoints New Director - Investing.com India
Omega Therapeutics Welcomes Robert Rosiello to Board - TipRanks
Omega Therapeutics Appoints New Director By Investing.com - Investing.com UK
Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors – Company Announcement - Financial Times
Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors - Quantisnow
A*STAR and Flagship Pioneering Announce Partnership to Spur Biotech Innovation in Singapore - Financial Times
Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer - Financial Times
Omega Therapeutics stock hits 52-week low at $1.2 By Investing.com - Investing.com Canada
Omega Therapeutics stock hits 52-week low at $1.2 - Investing.com
Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech Industry – Company AnnouncementFT.com - Financial Times
Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications - ForexTV.com
Omega Therapeutics reports tumor inhibition in liver cancer models - Investing.com
Omega Therapeutics Announces Publication of Epigenomic - GlobeNewswire
RNA-Based Therapeutics Market to Grow by USD 1.27 Billion (2024-2028) Due to Increased Investment and Funding, AI Trends Impacting RevenueTechnavio - The Malaysian Reserve
RNA-Based Therapeutics Market To Grow By USD 1.27 Billion (2024-2028) Due To Increased Investment And Funding, AI Trends Impacting RevenueTechnavio - MENAFN.COM
Omega Therapeutics (NASDAQ:OMGA) Stock Price Up 0.8% - MarketBeat
Omega Therapeutics (NASDAQ:OMGA) Shares Up 0.8% - Defense World
Omega Therapeutics stock hits 52-week low at $1.29 amid downturn - Investing.com Australia
A look into Omega Therapeutics Inc (OMGA)’s deeper side - SETE News
Omega Therapeutics inks shared space deals with Flagship affiliates - Investing.com
Omega Therapeutics inks shared space deals with Flagship affiliates By Investing.com - Investing.com South Africa
Novo Nordisk to meet Drug Demand with $220M Expansion - European Pharmaceutical Manufacturer
HC Wainwright Comments on Omega Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:OMGA) - MarketBeat
Omega Therapeutics Inc (OMGA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):